Kimberly B Shepard

Dr. Kimberly B Shepard

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2013 in Macromolecular Chemistry and Physics
Verified
Journal Article
Closed access
PDF file
KSKimberly B Shepard
Kimberly B Shepard
RPRodney D. Priestley
Rodney D. Priestley

17 January 2013 in The Journal of Physical Chemistry Letters
Verified
Journal Article
Closed access
CZChuan Zhang
Chuan Zhang
YGYunlong Guo
Yunlong Guo
KSKimberly B Shepard
Kimberly B Shepard
RPRodney D. Priestley
Rodney D. Priestley

31 August 2021 in AAPS PharmSciTech
Verified
Journal Article
Open access
PDF file
KSKimberly B Shepard
Kimberly B Shepard
DVDavid T. Vodak
David T. Vodak
PKPhilip J. Kuehl
Philip J. Kuehl
DRDavid Revelli
David Revelli
YZYue Zhou
Yue Zhou
MBMichael Banks
Michael Banks
Local delivery of biotherapeutics to the lung holds great promise for treatment of lung diseases, but development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge. Here, spray drying was used to manufacture a dry powder pulmonary formulation of bevacizumab, a monoclonal antibody approved to treat non-small cell lung cancer (NSCLC) by intravenous infusion. By reformulating bevacizumab for local delivery, reduced side effects, lower doses, and improved patient compliance are possible. The formulation had aerosol properties suitable for delivery to the deep lung, as well as good physical stability at ambient temperature for at least 6 months. Bevacizumab’s anti-VEGF bioactivity was not impacted by the manufacturing process. The formulation was efficacious in an in vivo rat model for NSCLC at a 10-fold decrease in dose relative to the intravenous control.

28 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MOMani Ordoubadi
Mani Ordoubadi
KSKimberly B Shepard
Kimberly B Shepard
HWHui Wang
Hui Wang
ZWZheng Wang
Zheng Wang
APAmanda Marie Pluntze
Amanda Marie Pluntze
RVReinhard Vehring
Reinhard Vehring
Carrier-free spray-dried dispersions for pulmonary delivery, for which the demand is growing, frequently require the incorporation of dispersibility-enhancing excipients into the formulations to improve the efficacy of the dosage form. One of the most promising of such excipients, L-leucine, is expected to be approved for inhalation soon and has been studied exhaustively. However, during stability, small fibers protruding from the particles of leucine-containing powders have occasionally been observed. To clarify the origin of these fibers and assess their potential influence on the performance of the powders, three different classes of spray-dried leucine-containing formulation systems were studied over an 8-month accelerated stability program. These systems consisted of a large molecule biologic (bevacizumab) in conjunction with a glass former (trehalose), an amorphous small-molecular mass active (moxidectin), and a crystallizing active (mannitol). It was determined that the appearance of the fibers was due to the presence of small quantities of leucine in higher energy states, either because these were amorphous or present as a less stable crystalline polymorph. It was further shown that the growth of these leucine fibers caused no significant physicochemical instability in the powders. Nor, more importantly, did it decrease their aerosol performance in a dry powder inhaler or reduce the concentration of their active pharmaceutical ingredients.

1 December 2020 in International Journal of Pharmaceutics: X
Verified
Journal Article
Open access
DMDeanna Mudie
Deanna Mudie
SBStephanie Buchanan
Stephanie Buchanan
ASAaron Stewart
Aaron Stewart
ASAdam Smith
Adam Smith
KSKimberly B Shepard
Kimberly B Shepard
DVDavid T. Vodak
David T. Vodak
Although Amorphous Solid Dispersions (ASDs) effectively increase bioavailability, tablet mass can be high due to the large fraction of excipients needed to stabilize the amorphous drug in the solid state, extend drug supersaturation in solution and achieve robust manufacturability. The aim of this work was to reduce tablet mass of an ASD tablet comprising a low glass transition temperature (Tg), rapidly crystallizing drug without compromising these key attributes. In this approach, erlotinib (Tg = 42 °C, Tm/Tg = 1.4 K/K) was spray dried with the high Tg polymer poly(methyl methacrylate-co-methacrylic acid) (Eudragit® L100, Evonik) (Tg = 187 °C) to facilitate high drug loading while maintaining physical stability. Hydroxypropyl methylcellulose acetate succinate (HPMCAS) (AQOAT® HF, Shin-Etsu) was granulated with the ASD to extend supersaturation in solution. For comparison, a benchmark ASD was spray dried at a lower drug loading with HPMCAS-H (Tg = 119 °C). This High Loaded Dosage Form (HLDF) approach reduced tablet mass by 40%, demonstrated similar physical stability and in vitro performance as the benchmark and exhibited excellent downstream manufacturability. Strategically combining two different polymers in a tablet to maintain physical stability and sustain supersaturation in solution can decrease tablet mass of some low Tg, rapidly crystallizing amorphous drugs.

10 December 2019 in Powder Technology
Verified
Journal Article
Open access
KSKimberly B Shepard
Kimberly B Shepard
Molly AdamMolly Adam
Molly Adam
MMMichael Morgen
Michael Morgen
DMDeanna M. Mudie
Deanna M. Mudie
DRDaniel T. Regan
Daniel T. Regan
DVDavid T. Vodak
David T. Vodak
Spray drying is one of the most broadly applicable and widely used methods of producing amorphous solid dispersions (ASDs). ASDs can improve the oral absorption of poorly water-soluble active pharmaceutical ingredients. Eudragit L100 is an appealing ASD excipient, due to its favorable impact on ASD physical stability and dissolution performance. However, spray drying Eudragit L100 can lead to high-aspect ratio filaments which reduce flowability, density and yield of the resulting powder. This negatively impacts downstream ASD performance and dosage form manufacturability. This work presents a mechanism for filament formation, which results in a particle engineering design space of key processing parameters, defined by a dimensionless parameter for assessing filament formation risk. Specifically, it was found that solution concentration, spray dryer inlet temperature and solvent volatility had the largest impact on controlling filament formation, based on their influence on the relative time scale to atomize versus droplet skinning during drying.